Russian Journal of Skin and Venereal Diseases最新文献

{"title":"Clinical and pathogenetic assessment of cyclosporine efficacy in the complex therapy of non-segmental vitiligo patients","authors":"A. S. Nikulina, K. Lomonosov","doi":"10.17816/dv625411","DOIUrl":"https://doi.org/10.17816/dv625411","url":null,"abstract":"BACKGROUND: Vitiligo is a chronic disease of unknown etiology, characterized by the appearance of depigmented spots on various areas of the skin, rarely on mucous membranes, and discolored hair due to destruction and reduction of melanocytes. While not life-threatening, vitiligo significantly impacts the psychoemotional aspect. Studies assessing the quality of life of vitiligo patients reveal the presence of depression in these individuals. In addition to depression, a high susceptibility to anxiety, stigmatization, sleep disturbances, adaptation, and problems in personal relationships have been identified. The prevalence of depression and anxiety among vitiligo patients is comparable to other dermatological conditions such as atopic dermatitis, acne, psoriasis, and urticaria. This underscores the need to seek new means and methods for treating this condition. \u0000AIM: Clinical assessment of the effectiveness of using cyclosporine in combination with UVB 311 nm and monotherapy with UVB 311 nm for vitiligo. \u0000MATERIALS AND METHODS: The study involved 40 patients with progressive vitiligo. All patients were randomly divided into two groups. Group 1 (20 individuals) underwent a course of cyclosporine therapy in combination with UVB therapy, while Group 2 (20 individuals) received monotherapy with UVB 311 nm. The duration of the treatment was 6 months. The extent of the affected area relative to the body surface area was evaluated using the VES index (Vitiligo extent score) on a vitiligo calculator. The impact of the disease on the quality of life was assessed using the VitiQoL scale (vitiligo-specific quality-of-life instrument). \u0000RESULTS: All patients included in the study completed the full course of treatment. Group 1 (20 individuals) underwent a course of cyclosporine therapy in combination with UVB therapy, while Group 2 (20 individuals) received monotherapy with UVB 311 nm. Patients in the combined therapy group experienced earlier stabilization of the skin process compared to those receiving monotherapy with UVB 311 nm. Additionally, Group 1 demonstrated more pronounced repigmentation of vitiligo lesions and significant improvement in quality of life compared to Group 2. \u0000CONCLUSION: Cyclosporine in combination with narrowband phototherapy at 311 nm demonstrated good clinical efficacy and significant improvement in quality of life for non-segmental vitiligo patients. Cyclosporine is well-tolerated, has a low spectrum of side effects, and can be used long-term for patients with active vitiligo.","PeriodicalId":507281,"journal":{"name":"Russian Journal of Skin and Venereal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140981738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deverji's disease after COVID-19: Case report","authors":"O. Y. Olisova, Natalya P. Teplyuk, Daria M. Martynenko, Ekaterina R. Dunaeva, E. Grekova","doi":"10.17816/dv623046","DOIUrl":"https://doi.org/10.17816/dv623046","url":null,"abstract":"Deverji's disease is a rare idiopathic skin disease characterized by keratinization disorder and manifested in follicular hyperkeratosis, orange-red peeling plaques, palmar-plantar keratodermia with the possible development of erythroderma. The etiopathogenesis of this dermatosis is still unknown. There are such possible trigger factors as traumatization, ultraviolet radiation, taking certain medications, autoimmune and oncological diseases, bacterial or viral infection, vaccination. The presence of familial cases is due to a mutation in the CARD14 gene. Diagnosis of the disease is based on characteristic clinical symptoms. The histological picture has no pathognomonic features; however, a biopsy is necessary for differential diagnosis with other papulosquamous dermatoses. Treatment of Deverji's disease remains a difficult task, since the disease pathogenesis has not been fully studied. \u0000The article describes a clinical case of Deverji's disease manifestation in a 64-year-old woman who had suffered COVID-19 infection twice. She was admitted to the Department of Dermatology and Venerology (Sechenov University) with complaints of skin rashes on her face, trunk, upper and lower extremities, accompanied by severe itching. The absence of any distinctive clinical and histological changes, the torpidity of the skin process and resistance to the therapy made it difficult to make a diagnosis. After the emergence of characteristic clinical symptoms (palmar-plantar keratodermia, salmon-tinged rashes with islands of healthy skin), as well as the results of repeated histological examination (alternating areas of ortho- and parakeratosis; uneven granular layer; vacuolization of basal cells; uneven broad acantholytic strands; loosened dermo-epidermal junction; small perivascular lymph-macrophage infiltrates) Deverji's disease was diagnosed. \u0000The use of standard therapies (systemic glucocorticosteroid therapy, methotrexate, topical therapy) did not give any results, and therefore it was decided to initiate the netakimab. After 5 injections, the first positive results were obtained in the form of the color paling and a decrease in the number of rashes, palmar-plantar keratodermia regression and improvement of the patient psychoemotional state. After 11 injections, almost complete remission was achieved, and treatment was continued until all symptoms disappeared completely. \u0000The article provides a literature review of the etiopathogenesis, clinical manifestations and treatment methods of Deverji's disease. The described clinical case is the fifth example in the world of the Deverji's disease manifestation after a COVID-19 infection, and is also the first case of the IL-17 inhibitor netakimab successful use for the disease treatment.","PeriodicalId":507281,"journal":{"name":"Russian Journal of Skin and Venereal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140265841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and clinical signs of inflammatory back pain in patients with skin psoriasis and axial involvement","authors":"N. Pereverzina, L. S. Kruglova, T. Korotaeva","doi":"10.17816/dv624169","DOIUrl":"https://doi.org/10.17816/dv624169","url":null,"abstract":"BACKGROUND: The incidence of psoriatic arthritis has been increasing in recent years. Moreover the number of severe cases resistant to standard therapy has been increasing as well and leading to a marked deterioration in the quality of life and early disability. There is a need to diagnose the disease at preclinical stages, as well as early therapy and secondary prevention. Therefore, the role of dermatologists in identifying predictors and risk factors for the development and severe course of psoriatic arthritis is increasing. Particularly severe forms of psoriatic arthritis are caused by axial manifestations, which are often clinically asymptomatic in early stage of psoriatic arthritis. Moreover, most often axial manifestations is diagnosed in patients with an already established diagnosis of psoriatic arthritis, and there is practically no data on the prevalence and clinical and instrumental characteristics of axial manifestations in patients with smooth skin psoriasis. \u0000AIM: to assess the prevalence and clinical characteristic of axial manifestations in patients with skin psoriasis using questionnaires, scales and Аssessment of SpondyloArthritis International Society (ASAS) diagnostic criteria. \u0000MATERIALS AND METHODS: The prospective study to assess the prevalence and clinical characteristiс of axial manifestations in patients with skin psoriasis. \u0000RESULTS: The prevalence of axial manifestations in patients with skin psoriasis, according to ASAS criteria, was 36.1%. Early manifestations of axial lesions in patients with skin psoriasis are aching, nagging pain in the back (37.2%) or neck (22.1%), as well as a feeling of stiffness in the back (46.3%) or neck (38.9%). The main risk factors and predictors of the development of psoriatic arthritis were the long duration of skin psoriasis (more than 12 years), pain in any joints, swelling of the fingers, pain/stiffness in the neck, pain/stiffness in the back, pain in the joints at rest/night time, widespread (BSA 18 points), severe (PASI 13 points) process. Having back/neck pain at rest or at night increases the odds of developing inflammatory pain by 132 times and 10 times, respectively, and back/neck stiffness by 10 and 6 times, respectively. Increasing the age of onset of back/neck pain by 1 year increases the chances of developing axial lesions by 1.3 times. \u0000CONCLUSION: There is the first study to identify clinical signs of inflammatory back pain in patient with axial manifestations at early stage of psoriatic arthritis and to determine the prevalence of inflammatory back pain in patients with skin psoriasis and without an established diagnosis of psoriatic arthritis. However, further study of methods for early diagnosis of axial manifestations and other forms of psoriatic arthritis is necessary to optimize treatment and improve the quality of life of patients.","PeriodicalId":507281,"journal":{"name":"Russian Journal of Skin and Venereal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronicles of A.I. Pospelov Moscow Society of Dermatovenerologists and Cosmetologists (MSDС was founded on October 4, 1891) Bulletin of the MSDС № 1155","authors":"A. B. Yakovlev, I. Maximov, Eugenia V. Petukhova","doi":"10.17816/dv626632","DOIUrl":"https://doi.org/10.17816/dv626632","url":null,"abstract":"On December 19th we held our last meeting of Moscow Society of Dermatologists and Cosmetologists named after A.I. Pospelov in person. \u0000There were 137 participants and no applicants. \u0000Professors, teachers and doctors from leading dermatovenerological clinics in Moscow were invited to take part in the anniversary meeting of the MSDС. \u0000Our agenda included two clinical cases. Both of them were based on speakers’ personal experience and included nail and facial skin disorders. This kind of analysis may boost doctors’ experience in diagnosis and management of challenging clinical cases. \u0000There were no scientific reports of the meeting.","PeriodicalId":507281,"journal":{"name":"Russian Journal of Skin and Venereal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic determinants of atopic dermatitis","authors":"Inna P. Grebennikova, Anna V. Morrison, T. E. Lipatova, Maria G. Yeremina","doi":"10.17816/dv607439","DOIUrl":"https://doi.org/10.17816/dv607439","url":null,"abstract":"Atopic dermatitis is a heterogeneous disease, the pathogenesis of which is associated with mutations of genes encoding structural proteins of the epidermis, barrier enzymes and their inhibitors. \u0000The article analyzes data from the works of various authors on the study of gene expression in atopic dermatitis, and notes the role of genes regulating innate and adaptive immune responses, as well as environmental factors inducing the disease. Recent studies indicate a key role of epigenetic changes in the development of the disease. Epigenetic modifications are mainly mediated by DNA methylation, histone acetylation and the action of specific non-coding RNAs. It has been documented that the profile of epigenetic changes in patients with atopic dermatitis differs from that observed in healthy individuals. \u0000Understanding epigenetic changes is critical for developing personalized treatment strategies.","PeriodicalId":507281,"journal":{"name":"Russian Journal of Skin and Venereal Diseases","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140266699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}